Therapeutic Research Protocol Dose: 5.0 10.0 mg (= 100200 clicks) Duration: 3 consecutive days per cycle Frequency: 1 cycle every 3 4 weeks Cycle Interval: 3 4 weeks off before repeating Goal / Description: Higher-dose pulse evaluated for accelerated senescent cell clearance in research models
The combination of dasatinib and quercetin (DQ) has completed phase 1 clinical trials for Alzheimers disease, and navitoclax is currently in phase 3 clinical trials for myelofibrosis 29,30
Muller recommends Manuka honey in two forms: drops and gel
Franco M, Roswall P, Cortez E, Hanahan D, Pietras K
Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2) should discuss this with their clinician before considering any GLP-1based therapy, and should be alert to symptoms such as a neck lump, hoarseness, or difficulty swallowing
A neuroradiologists guide to arterial spin labeling MRI in clinical practice